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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not L-theanine,
an amino acid analogue found in green tea leaves, is an effective treatment for reducing anxiety
in patients ages 18-25.
Study design: Review of two double-blind, randomized controlled studies and one single-blind,
randomized controlled study published in 2007, 2012 and 2013 respectively.
Data sources: PubMed
Outcome(s) measured: Each study measured L-theanine’s ability to reduce acute anxiety with a
series of self-report measures assessing acute anxiety and stress, including the Profile of Mood
States (POMS), the visual analogue scales (VAS), State-Trait Anxiety Inventory (STAI) and
achievement emotion measurement.
Results: Kimura and colleagues found that state-trait anxiety inventory scores were significantly
lower in the L-theanine group compared to placebo, Yoto and colleagues found that L-theanine
significantly decreased tension-anxiety scores compared to placebo and Unno and colleagues
found that scores of subjective stress were significantly lower in the L-theanine group compared
to placebo.
Conclusion: Each reviewed study provides convincing and statistically significant evidence that
that L-theanine has the potential to reduce symptoms of anxiety. However, there were
inconsistencies. All three studies used VAS as a self-report measure, but only Unno and
colleagues found VAS scores to be significantly reduced. Similarly, STAI scores were only
significantly lowered in the study by Kimura and colleagues. Despite these discrepancies, the
studies demonstrate a likely benefit of L-theanine reducing anxiety-related symptoms.
Key words: L-theanine, anxiety
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INTRODCTION
Anxiety affects millions of people worldwide with devastating, life altering
consequences. It is defined as an individual’s emotional and physical fear response to a
perceived threat1. When symptoms are excessive, irrational, out of proportion to the trigger or
are without an identifiable trigger, it is considered to be pathologic1. Anxiety can hugely impact
a patient’s day to day life as it can lead to excessive stress, sleep disturbance and fatigue. With
the ever growing fitness crazes, approaches to living a more “clean,” healthy lifestyle, and the
growing popularity of alternative therapies, there is a market for treating anxiety with alternative
approaches. Consequently, it is relevant to see whether L-theanine, a natural element of green
tea, can effectively reduce anxiety in patients.
Physician Assistants have been working in the field of psychiatry since 19752. With
approximately 100,000 PAs practicing in the United States, approximately 1,500 work in
psychiatry. Although psychiatry is a specialty with few PAs, there is a huge demand according to
the AAPA2. PAs can work in behavioral health facilities, psychiatry units of hospitals and private
practice where they can conduct initial assessments and perform maintenance check ups.
Generalized anxiety disorder (GAD) in patients has an estimated lifetime prevalence of
5% and a 1-year prevalence of 3%3. Furthermore, patients with anxiety disorders are three to five
times more likely to go to the doctor and six times more likely to be hospitalized for psychiatric
disorders than those who do not suffer from anxiety disorders. With 3% of the U.S. diagnosed
with generalized anxiety disorder, it is undeniable that PAs will encounter GAD not just in the
field of psychiatry, but in family medicine and other specialties as well3. As the most common
form of psychopathology, it is not surprising that anxiety makes up 1/3 of the cost to treat mental
health disorders in the U.S at $42 million per year. Walmart, the most popular store in the United
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States, sells a package of 20 green tea bags for $2.42 4. At .12¢ per bag, L-theanine could serve
as an inexpensive and accessible alternative for treatment.
Despite the fact that 3% of the U.S. population has anxiety, there is no single etiology
that is known to exist. It proposed that the origin of anxiety is multifactorial, such as an increase
in stressors, physical and or emotional trauma and genetic factors1. Although the
pathophysiology is not well understood either, neurotransmitter receptors of serotonin, NMDA,
and glutamate are thought to play a role. In order to be diagnosed, patients most have excessive
worry for at least 6 months, in addition to three of the following: restlessness, fatigue, impaired
concentration, irritability, muscle tension and insomnia1. Traditionally, anxiety is treated with
antidepressants such as SSRIs (ie sertraline, escitalopram) and SNRIs. An additional option is a
benzodiazepine. To enhance the effectiveness of drug therapy, cognitive behavioral therapy is
crucial in helping patients learn how to cope with their worry habits. Other options include
relaxation, meditation, exercise and reading self-help books. Despite the effectiveness of SSRIs,
there are numerous side effects, such as sexual dysfunction, drowsiness, headache and stomach
upset1. Therefore, L-theanine could serve as a potential alternative and or an additional option for
patients dealing with side effects, or who want to avoid the addictive component of
benzodiazepines.
Similar to benzodiazepines which exert their effects by interacting with GABA receptors,
L-theanine blocks the binding of L-glutamic acid to glutamate receptors in the brain5. Exposure
to acute or chronic stress results in glutamate increase. An increase in glutamate also results in
hyper-activation of the sympathetic nervous system (SNS). MRI studies have shown that the
brain regions associated with anxiety such as the amygdala and hippocampus are glutamate rich
and hyperactive in patients with anxiety disorders6. Therefore, because L-theanine blocks
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glutamate receptors, it is being proposed as a potential method to reduce anxiety. It is important
to note that although anxiety does not directly cause hypertension, repeated elevations in blood
pressure can lead to hypertension over time. This is because constant stress and worry can
stimulate the nervous system to produce vasoconstricting hormones. Consequently, because
glutamate stimulates the SNS, L-theanine has the potential to not only reduce psychological
symptoms of anxiety, but the physiological symptoms as well.
OBJECTIVE
The objective of this systematic review is to determine whether or not L-theanine, an
amino acid analogue found in green tea leaves, is an effective treatment for reducing anxiety in
patients ages 18-25. Three scholarly articles were selected for this systematic review, each
meeting the same specific criteria. Each article consisted of a study pool between the ages of 18
and 25 and used 200mg L-theanine PO as the intervention. The articles used the same
comparisons: a treatment group receiving L-theanine compared to the experimental group who
received a visually matched placebo. Two of the articles were randomized, double-blind placebo
controlled studies, while one was a randomized, single-blind placebo controlled study. In order
to measure L-theanine’s ability to alleviate stress and anxiety, the studies used a visual analog
scale (VAS), profile of mood states (POMS) and the state-trait anxiety inventory (STAI).
METHODS
The articles that compose this systemic review were accessed through PubMed. In order
to obtain the articles, key words searched were “anxiety” and “L-theanine.” All three articles
were published in English within the last 10 years and were selected because they met the criteria
discussed above, in addition to measuring patient oriented outcomes (POEMS). Inclusion criteria
included participants between ages 18-25 with no mental health history and articles published in
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English between the year 2000 and present. Exclusion criteria included participants under 18 or
over 25, participants with a mental health history, and articles published before year 2000 and
not published in English. Among the three articles, statistic reports used were p-value, fischer’s
z-test, one-way ANOVA, two-way ANOVA, x2, F-score and post hoc analysis with Least
Significant Difference (LSD) tests and Tukey’s honestly significant difference (HSD) tests.
Table 1: Demographics and Characteristics of Included Studies
Study
Unno
(2013)

Type

#
Age
Pts
Randomized, 20 Intervention=22.5
single-blind
+/- .2yrs
study
Control=22/2 +/.1 yrs

Kimura Double(2007) blind,
randomized
study

12

21.5

Yoto
(2012)

16

22.8 +/- 2.1 years

Doubleblind,
randomized
study

Inclusion
Criteria
Healthy, 5th
year
university
students

Exclusion W/D Interventions
Criteria
If students 0
200mg Lhad
Theanine
consumed
caffeinated
beverages
throughout
the
experiment.
Healthy
If students 0
200mg Lundergraduate had taken
Theanine
students who any
dissolved in
weren’t
medication
water
suffering
that could
from chronic influence
or oral
results
illnesses
Healthy
If students 2
200mg Lstudents who had drank
Theanine
weren’t
or eaten
suffering
anything
from chronic but water
or oral
prior to the
illnesses
start of
each trial

OUTCOMES MEASURED
A variety of outcomes were measured among the three trials. In the study conducted by
Yoto and colleagues5, the following measurements were used: participants completed a
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subjective assessment with The Profile of Mood States (POMS) and the visual analogue scales
(VAS). POMS measured six identifiable moods such as tension-anxiety and depression, while
VAS measured feelings of fatigue, relaxation, arousal, pleasure and tension. In the study
conducted by Kimura and colleagues7, the VAS and State-Trait Anxiety Inventory (STAI) were
used. The STAI had 20 items for assessing trait anxiety (i.e. “I worry too much over something
that really doesn’t matter”) and 20 items for assessing state anxiety (i.e. “I am worried,” “I feel
calm”). In Uno and colleagues study8, participants completed the STAI, VAS and an
achievement emotion measurement before the administration of L-theanine.
RESULTS
In the study conducted by Yoto and colleagues5, 16 healthy participants averaging 22.8
years old were originally enrolled and 2 participants withdrew due to temporary illness. The
patients were randomized to receive 200mg of L-theanine, placebo or caffeine (caffeine will not
be discussed as it is not relevant to objective) on 3 study days, 7 days apart. Participants were
instructed to not eat or drink anything but water prior to the task. Participants were placed in a
quiet room and relaxed for 15 minutes. They completed VAS and POMS before the task and
taking L-tehanine, and after the task and taking L-theanine. Prior to the initial statistical analysis,
separate, one-way, repeated measures ANOVAs of baseline data were conducted to account for
any baseline differences across “study days prior to the treatments.” A Tukey’s honestly
significant difference (HSD) post hoc test was then applied to data groups with significant main
effect. The POMS score indicated significant scores: tension-anxiety and anger-hostility scores
showed treatment effects over the two groups together (x2=6.000, 6.048, P=0.05, 0.049) and Ltheanine intake decreased tension-anxiety score below that in the placebo condition (P=0.004).
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No differences were obtained among treatments through VAS assessments. All of the data was
continuous and not convertible to dichotomous format.
Table 2: Changes in POMS scores from base line
Tension-

Depression- Anger-

Vigor-

Fatigue

Confusion-

Anxiety

Dejection

Hostility

Activity

Placebo

6.1

5.2

5.6

.7

6.9

7.4

LTheanine

.98

.5

2.8

.98

1

1.6

bewilderment

In the study conducted by Unno and colleagues8, 20 healthy 5th year pharmacy students
composed the participant pool (no participants withdrew). The students were assigned to practice
in a hospital or drug store setting for 11 weeks. Because the first 10 days of practice were
assumed to be the most stressful and anxiety-provoking, these days were analyzed. The
participants were randomly divided and began taking 200mg L-theanine or placebo (twice a day,
after breakfast and lunch) 7 days prior to beginning clinical practice, and then an additional 10
days once beginning clinical practice. The patients were instructed to avoid caffeinated
beverages throughout the experiment. The STAI, subjective stress (VAS) and achievement
emotion measurement were completed each of the 17 days. There was no significant difference
found in STAI values between the control and L-theanine group. However, the average VAS
score was significantly lower in the L-theanine group than in the placebo group (p=.020;one-way
ANOVA). There were no statistically significant achievement emotion results. All of the data
was continuous and not convertible to dichotomous format.
Table 3: Characteristics of the placebo-group and the L-theanine-group
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Age

Men/women

STAI value

Placebo

22/2 +/- .1
yrs

7/3

Theanine

22.5
+/- .2yrs

7/3

P-value

41 +/- 2.9

Subjective
stress (VAS
0-10)
4.07 +/- .33

Achievement
emotion
(score: 1-5)
3.26 +/- .07

41.9 +/- 2.4

3.10 +/- .25

3.19 +/- .06

Not
significant

p=.020

Not
significant
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In the study conducted by Kimura and colleagues7, the participant pool consisted of 12
healthy undergraduate students averaging the age of 21.5 not suffering from chronic illnesses.
Each participant was randomly assigned to participate in four experimental conditions on four
separate occasions: oral administration of L-theanine at the start of the session, oral
administration of L-theanine after the first stress task, no administration of any treatment, and
placebo administration at the start of the session. The order in which the participants were
assigned to each condition was formed using a Latin square design. Psychological measures used
were the STAI and VAS. Participants were asked to consume no food or beverages but water the
morning of and began the task after a 20 minute rest period in an experimental chamber. VAS
and STAI measures were completed after the arithmetic task, then 10 and 20 minutes post task.
Two-way ANOVAs revealed significant interactions between the condition and period in
perception of stress (F(6.83)=3.91, p<.01) and state of anxiety (F (6, 80)=4.29, p<.01). It was
also found that change of scores in subjective stress in both L-theanine conditions were
significantly lower than the two control conditions. Furthermore, the STAI state anxiety score
was significantly higher under the placebo condition compared to the L-theanine conditions.
Overall, no differences were found with taking L-theanine at different times. All of the data was
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continuous and not convertible to dichotomous format. The data was analyzed using ANOVAs
and any significant interactions found underwent post hoc analysis using LSD tests (p<.05).
Table 5: Means (S.D.s) of change scores from baseline scores in state anxiety score
Condition

Task

Rest 1

Rest 2

Control

1.83 (4.15)

.82 (4.13)

.08 (4.98)

Placebo

11.58

0.00 (3.9)

-1.67 (4.54)

L-theanine 1

1.58 (7.32)

-1 (3.98)

-1.92 (5.66)

L-theanine 2

3.17 (10.06)

.33 (5.14)

-1.08 (4.10)

DISCUSSION
In 2006, the FDA approved L-theanine as GRAS (Generally Recognized as Safe)9. This
includes the approved use as a food product in fruit juices, tea, chewing gum, specialty bottled
waters, etc. According to the FDA, there is 153-382mg of L-theanine per 12 oz of tea,
corresponding to the 200mg of L-theanine used in the discussed studies. The FDA also reviewed
a series of toxicity studies that found L-theanine to be non-toxic and safe at levels up to 4000mg
per kg of body weight. Presently, L-theanine is most commonly marketed for its ability to
promote relaxation in 200mg supplement form10. However, there is no research that definitively
supports these claims, and experts recommend that patients consume L-theanine through tea
rather than supplements. Despite L-theanine’s potential to treat anxiety, a condition that affects
up to 40 million people in the US alone, few are aware of its existence. This is especially ironic
as L-theanine is inexpensive and easily accessible on the shelves of all grocery stores across
America and free of the burdens of insurance and expensive prices.
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Although not pertinent to the objective, it is important to note that two of the studies
measured physiologic responses to anxiety. Unno and colleagues8 measured salivary amylase
activity levels (sAA) as markers of sympathetic nervous system activity (a higher sAA value
represents higher stress and anxiety levels). They found that the placebo-group showed a
tendency of higher sAA levels than the L-theanine group (p=.049). Additionally, Kimura and
colleagues7 found that the placebo group had higher heart rates and sAA levels than the Ltheanine group. Since increased heart rate and salivary production are associated with heightened
anxiety1, these findings further support the proposed objective.
Each study has limitations that must be acknowledged. First, each study utilized self
report measures, which makes the results susceptible to reactivity and subjectivity. Each
participant could have their own interpretation or understanding of anxiety, introducing a
participant bias. For instance, a participant who was a math major may have found the arithmetic
tasks less anxiety provoking than a participant who was an art major. Each study also took place
over an extended period of time, so participants grew familiar with the anxiety questions and
stressful arithmetic tasks. The participants could have inferred the study’s objective, falling
subject to demand characteristics. Internal validity is also compromised as the same tasks were
completed by the same participants on multiple days. Furthermore, participants could have
reported improvements in anxiety level simply because they knew they were receiving some type
of treatment, introducing a response bias. Next, the small simple size compromises the external
validity of the study. Further weakening the generalizability is the fact that the limited
participants used were all students. Additionally, Kimura and colleagues only used male
participants, calling into question the external validity of their results. External validity is also
compromised in the study by Unno and colleagues because all of the participants were pharmacy
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students. Pharmacy students could be more biased toward the efficacy of drugs compared to the
general public due to their specialized medical background.
CONCLUSION
The studies reviewed provide convincing and statistically significant evidence that Ltheanine has the potential to reduce symptoms of anxiety. Kimura and colleagues7 found that
state-trait anxiety inventory scores were significantly lower in the theanine group compared to
placebo, Yoto and colleagues6 found that L-theanine significantly decreased tension-anxiety
scores compared to placebo and Unno and colleagues8 found that scores of subjective stress were
significantly lower in the L-theanine group compared to placebo. Furthermore, L-theanine
significantly reduced HR and salivary production compared to placebo in two of the studies,
further bolstering L-theanine’s ability to not just reduce psychological symptoms of anxiety, but
physical. Nonetheless, it can only be said that L-theanine has the “potential” to reduce symptoms
of anxiety as there were discrepancies among the studies. All three studies used VAS as a selfreport measure. However, only Unno and colleagues8 found that L-theanine significantly reduced
VAS scores. Additionally, two studies used STAI as a measurement, but only Kimura and
colleagues7 found that L-theanine significantly reduced STAI scores. Although each study found
results favoring L-theanine’s ability modify anxiety, these inconsistencies makes it difficult to
arrive at a definitive conclusion.
It is important to conduct future studies that account for the limitations in the discussed
articles. None of the participants used were diagnosed with GAD. Therefore, it can only be said
that L-theanine may reduce symptoms of anxiety in healthy patients. It would be helpful and
beneficial for future studies to use participants diagnosed with GAD, that way a conclusion can
be drawn about pathologic anxiety. Additionally, two of the three studies did not have
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participants take L-theanine daily, only when they underwent acute stress tasks. It is possible that
L-theanine may work similarly to a benzodiazepine and treat sudden, acute symptoms of anxiety.
It would be curious to see whether L-theanine can work like an SSRI and provide daily
maintenance therapy. To answer this question, future experiments should utilize a longitudinal
study and require a large simple of participants diagnosed with GAD to take L-theanine daily for
an extended period of time. Aside from anxiety, research with L-theanine is being explored in
PTSD, schizophrenia, hypertension, attention and insomnia to name a few. As a cost-effective
and easily accessible supplement in a time where clean-living is more popular than ever, it is
clear that L-theanine has the potential to become highly utilized in not just anxiety, but a variety
of conditions.
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